Clinuvel Pharmaceuticals – Minimal Concerns Over FDA Delay

By Tim McGowen | More Articles by Tim McGowen

Clinuvel Pharmaceuticals has announced that the US Food and Drug Administration (FDA) Division of Dermatology and Dental Products has set a new Prescription Drug User Fee Act (PDUFA) goal date of 6 October 2019 to provide it with more time for a full review of the submission of its SCENESSE® scientific dossier.

Analysts at Moelis note that while any delay around FDA approval is disappointing, given it will push back first sales in the US by at least 3 months, they are not concerned that the hold up is a sign of anything sinister. Rather its likely only a timing issue.

For full details click here to download the research report.

Tim McGowen

About Tim McGowen

Tim McGowen is the co-founder of informedinvestor.com.au. He was previously the founder of Fortitude Capital the Hedge fund of the Year in 2008 & 2009. More recently he was a global Portfolio Manager for PM Capital.

View more articles by Tim McGowen →